{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:51:58Z","timestamp":1773319918627,"version":"3.50.1"},"reference-count":31,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Definitive radiotherapy (dRT) has been shown to be an effective option for patients with oligometastatic and oligoprogressive cancers; however, this approach has not been well-studied in metastatic thyroid cancer. <jats:bold>Methods:<\/jats:bold> This retrospective cohort included 119 patients with oligometastatic (34%) and oligoprogressive (66%) metastatic thyroid cancer treated from 2005 to 2024 with 207 dRT courses for 344 sites (50% thoracic, 37% bone, 7.5% brain, 4% abdominopelvic, and 1.5% neck\/skull base). Histologies included 61% papillary, 15% poorly differentiated, 13% follicular, and 10% oncocytic, and 114 (96%) patients had radioiodine-refractory disease prior to dRT. Each course involved 1 to 5 sites, with prescriptions intended for definitive control (median BED10, 72 Gy), and palliative RT was excluded. Somatic mutation testing for oncologic drivers was performed in 103 (87%) patients. <jats:bold>Results:<\/jats:bold> Each patient had an average of 3 sites (range, 1\u201323) treated over 2 courses (range, 1\u20139). Follow-up from first dRT was a median 2.5 years, with overall survival at 3 and 5 years of 81.5% and 70%, respectively. Actuarial local control per site was 91% at 3 years. Median progression-free survival (PFS) after first course was 17 months (95% CI, 10\u201324 months), with poorly differentiated histology associated with worse outcomes (hazard ratio [HR], 2.20; 95% CI, 1.24\u20133.90; P=.007), BRAF mutation with improved PFS (HR, 0.59; 95% CI, 0.37\u20130.95; P=.029), and no significant findings with respect to systemic therapy. At initial dRT, 92 (77%) patients were not on systemic therapy; and after first dRT, freedom from systemic therapy escalation was a median 4.1 years (95% CI, 1.7\u20136.5 years), with 2- and 5-year continued deferral rates of 73% and 46%, respectively. Grade 3 toxicities were noted for 1.5% of courses, with no grade 4\u20135 events observed. <jats:bold>Conclusions:<\/jats:bold> This study underscores the potential of dRT as a feasible strategy for deferring systemic therapy escalation in patients with oligometastatic and oligoprogressive metastatic thyroid cancer, demonstrating that sequential dRT courses impart excellent local control and are safe to deliver repeatedly for multiple distant sites. Further studies are warranted to validate these findings and elucidate the full benefit of dRT as part of a multidisciplinary approach for metastatic thyroid cancer.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7072","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:26:24Z","timestamp":1733945184000},"source":"Crossref","is-referenced-by-count":4,"title":["Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral"],"prefix":"10.6004","volume":"23","author":[{"given":"Stephanie O.","family":"Dudzinski","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hamidi","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente R.","family":"Marczyk","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naifa L.","family":"Busaidy","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Dadu","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Welsh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi I.","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Brandon","family":"Gunn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Phan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Beckham","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven I.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay P.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita K.","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumil J.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quynh-Nhu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Zafereo","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel RL","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7\u201330."},{"key":"B2","series-title":"Endocr Pract","first-page":"1048","article-title":"Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer","volume":"22","author":"Chen P","year":"2016","unstructured":"Chen P, Feng HJ, Ouyang W,  Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer. Endocr Pract 2016;22:1048\u20131056."},{"key":"B3","series-title":"Ann Surg","first-page":"114","article-title":"Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors","volume":"251","author":"Lee J","year":"2010","unstructured":"Lee J, Soh EY. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors. Ann Surg 2010;251:114\u2013119."},{"key":"B4","series-title":"Lancet","first-page":"2783","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas ME","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016;388:2783\u20132795."},{"key":"B5","series-title":"J Clin Endocrinol Metab","first-page":"2892","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma","volume":"91","author":"Durante C","year":"2006","unstructured":"Durante C, Haddy N, Baudin E,  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2892\u20132899."},{"key":"B6","series-title":"Lancet Oncol","first-page":"1126","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311)","volume":"22","author":"Brose MS","year":"2021","unstructured":"Brose MS, Robinson B, Sherman SI,  Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311). Lancet Oncol 2021;22:1126\u20131138."},{"key":"B7","series-title":"N Engl J Med","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger M","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ,  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621\u2013630."},{"key":"B8","series-title":"Endocrine","first-page":"358","article-title":"Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution","volume":"73","author":"Porcelli T","year":"2021","unstructured":"Porcelli T, Luongo C, Sessa F,  Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine 2021;73:358\u2013366."},{"key":"B9","series-title":"Lancet","first-page":"319","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose MS","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B,  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319\u2013328."},{"key":"B10","series-title":"Ann Endocrinol (Paris)","first-page":"1S40","article-title":"Local treatment of metastases from differentiated thyroid cancer","volume":"76","author":"Bonichon F","year":"2015","unstructured":"Bonichon F, Buy X, Godbert Y,  Local treatment of metastases from differentiated thyroid cancer. Ann Endocrinol (Paris) 2015;76:1S40\u201346."},{"key":"B11","series-title":"Lancet Oncol","first-page":"e18","article-title":"Characterisation and classification of oligometastatic disease: an ESTRO and EORTC consensus recommendation","volume":"21","author":"Guckenberger M","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB,  Characterisation and classification of oligometastatic disease: an ESTRO and EORTC consensus recommendation. Lancet Oncol 2020;21:e18\u201328."},{"key":"B12","series-title":"Lancet Oncol","first-page":"1672","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy","volume":"17","author":"Gomez DR","year":"2016","unstructured":"Gomez DR, Blumenschein GR, Lee JJ,  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. Lancet Oncol 2016;17:1672\u20131682."},{"key":"B13","series-title":"Lancet","first-page":"2051","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)","volume":"393","author":"Palma DA","year":"2019","unstructured":"Palma DA, Olson R, Harrow S,  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET). Lancet 2019;393:2051\u20132058."},{"key":"B14","series-title":"JAMA Oncol","first-page":"825","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang C","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C,  Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol 2023;9:825\u2013834."},{"key":"B15","series-title":"Cancer","first-page":"4572","article-title":"Isolated progression of metastatic lung cancer: clinical outcomes associated with definitive radiotherapy","volume":"126","author":"Friedes C","year":"2020","unstructured":"Friedes C, Mai N, Fu W,  Isolated progression of metastatic lung cancer: clinical outcomes associated with definitive radiotherapy. Cancer 2020;126:4572\u20134583."},{"key":"B16","series-title":"Radiother Oncol","first-page":"493","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke CA","year":"2018","unstructured":"Pembroke CA, Fortin B, Kopek N. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. Radiother Oncol 2018;127:493\u2013500."},{"key":"B17","series-title":"Lancet","first-page":"171","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study","volume":"403","author":"Tsai CJ","year":"2023","unstructured":"Tsai CJ, Yang JT, Shaverdian N,  Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 2023;403:171\u2013182."},{"key":"B18","series-title":"Adv Radiat Oncol","first-page":"101500.","article-title":"Radioresistant pulmonary oligometastatic and oligoprogressive lesions from nonlung primaries: impact of histology and dose-fractionation on local control after radiation therapy","volume":"9","author":"Verma N","year":"2024","unstructured":"Verma N, Laird JH, Moore NS,  Radioresistant pulmonary oligometastatic and oligoprogressive lesions from nonlung primaries: impact of histology and dose-fractionation on local control after radiation therapy. Adv Radiat Oncol 2024;9:101500."},{"key":"B19","series-title":"Lancet Oncol","first-page":"1732","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma","volume":"22","author":"Tang C","year":"2021","unstructured":"Tang C, Msaouel P, Hara K,  Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma. Lancet Oncol 2021;22:1732\u20131739."},{"key":"B20","series-title":"Lancet Oncol","first-page":"e193","article-title":"Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma","volume":"25","author":"Marvaso G","year":"2024","unstructured":"Marvaso G, Jereczek-Fossa BA, Zaffaroni M,  Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma. Lancet Oncol 2024;25:e193\u2013204."},{"key":"B21","article-title":"NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 3.2024","author":"Haddad RI","unstructured":"Haddad RI, Agosto Salgado S, Applewhite M,  NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 3.2024.  Accessed August 1, 2024. To view the most recent version, visit https:\/\/www.nccn.org\/"},{"key":"B22","series-title":"J Clin Endocrinol Metab","first-page":"3698","article-title":"Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine","volume":"103","author":"Jaber T","year":"2018","unstructured":"Jaber T, Waguespack SG, Cabanillas ME,  Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. J Clin Endocrinol Metab 2018;103:3698\u20133705."},{"key":"B23","series-title":"Cancer","first-page":"2281","article-title":"Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial","volume":"128","author":"Kiyota N","year":"2022","unstructured":"Kiyota N, Tahara M, Robinson B,  Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 2022;128:2281\u20132287."},{"key":"B24","series-title":"Eur Thyroid J","first-page":"185","article-title":"European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions","volume":"10","author":"Mauri G","year":"2021","unstructured":"Mauri G, Heged\u00fcs L, Bandula S,  European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021;10:185\u2013197."},{"key":"B25","series-title":"Curr Opin Oncol","first-page":"15","article-title":"Oligometastatic disease from differentiated thyroid cancer: best treatment schemes","volume":"35","author":"Colombo E","year":"2023","unstructured":"Colombo E, Ottini A, Licitra L. Oligometastatic disease from differentiated thyroid cancer: best treatment schemes. Curr Opin Oncol 2023;35:15\u201321."},{"key":"B26","series-title":"Radiol Med","first-page":"681","article-title":"Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review","volume":"127","author":"Lancellotta V","year":"2022","unstructured":"Lancellotta V, Fanetti G, Monari F,  Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review. Radiol Med 2022;127:681\u2013689."},{"key":"B27","series-title":"Future Oncol","first-page":"21","article-title":"Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib","volume":"15","author":"Porcelli T","year":"2019","unstructured":"Porcelli T, Sessa F, Gambale C,  Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. Future Oncol 2019;15:21\u201325."},{"key":"B28","series-title":"Thyroid","first-page":"1269","article-title":"Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I\/II trials","volume":"26","author":"Bernstein MB","year":"2016","unstructured":"Bernstein MB, Chang EL, Amini B,  Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I\/II trials. Thyroid 2016;26:1269\u20131275."},{"key":"B29","series-title":"J Clin Endocrinol Metab","first-page":"3637","article-title":"Prognosis and treatment of brain metastases in thyroid carcinoma","volume":"82","author":"Chiu AC","year":"1997","unstructured":"Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637\u20133642."},{"key":"B30","series-title":"Int Surg","first-page":"490","article-title":"Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients","volume":"100","author":"Brient C","year":"2015","unstructured":"Brient C, Mucci S, Ta\u00efeb D,  Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients. Int Surg 2015;100:490\u2013496."},{"key":"B31","series-title":"Cancers (Basel)","first-page":"4429","article-title":"Current management of bone metastases from differentiated thyroid cancer","volume":"13","author":"Kato S","year":"2021","unstructured":"Kato S, Demura S, Shinmura K,  Current management of bone metastases from differentiated thyroid cancer. Cancers (Basel) 2021;13:4429."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/1\/article-e247072.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/1\/article-e247072.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/1\/article-e247072.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T13:55:30Z","timestamp":1736949330000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/1\/article-e247072.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7072","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}